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1Chapter
Newer Modalities in the Treatment 
of Type 2 Diabetes Mellitus: Focus 
on Technology
Alan B. Schorr
Abstract
This chapter will focus on the technological advances for individuals with Type 
2 diabetes mellitus and their effect on treatment, control of blood glucoses and 
possible improvement in lifestyle and decreasing complications. This is a general 
overview of technological improvements and not an outline for specific patient 
care. Various technologies will be discussed and the outlook for future improve-
ments outlined.
Keywords: CSII-continuous subcutaneous insulin infusion, CGM-continuous glucose 
monitoring, HbA1C, MDI-multiple dose injection, smart pen
1. Introduction
During the past 30 years, there has been significant advances in technology 
for the treatment of patients with Diabetes Mellitus. Most of these advances have 
focused on patients with Type 1 diabetes mellitus. The perception has been that 
individuals with Type 2 diabetes mellitus have not needed these advances or that 
they are not appropriate for a population that does not always require insulin.
Type 2 diabetes mellitus is a disease which is multifactorial: linked to metabolic 
derangements, Obesity, dietary behavior along with lifestyle issues particularly 
those individuals who are Sedentary [1, 2]. Given these factors, technology has been 
considered as adjunct therapeutic modalities to use in addition modification of diet, 
education, medications and lifestyle changes.
2. Insulin pump therapy (CSII)
Continuous Subcutaneous Insulin Infusion (CSII) has been utilized since 
the 1970s for the treatment of Diabetes Mellitus. The first insulin pumps were 
extremely large and bulky. Dr. Arnold Kadish devised a backpack insulin pump in 
the 1960s, but it proved to be less than optimal for everyday use. Dean Kamen in the 
late 1970s developed a more practical portable insulin pump which was eventually 
produced by Baxter called the Auto Syringe. This was the initial insulin pump that 
this author utilized in the early 1908s. Insulin pumps have evolved significantly over 
the past 40 years becoming smaller, more precise in the delivery of insulin doses 
and more reliable than their older versions [3]. During the 1980s to early 2000s, 
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there were several companies providing insulin pumps to the public. Due to vary-
ing factors, these companies ceased production and in the late 2000s, there were 
only 4–5 companies in the US. As of 2018, there are only three large companies still 
functioning in the USA: Medtronic Diabetes, Omnipod and Tandem. There are 
several more companies in Europe that are providing insulin pumps. In the future 
there may be additional entries into the US market from other companies. Patch 
pumps are of particular interest to many individuals with DM.
The use of continuous subcutaneous insulin infusion as a primary therapy for 
Type 2 DM patients has been investigated for the past 40 years. It has been utilized 
in various patient groups, including those who have newly diagnosed Type 2 DM. It 
is noted that individuals with Type 2 DM have poor to average control [4].
Multiple uncontrolled studies from 2008 to 2013 evaluated insulin pump therapy 
(CSII) in patients with Type 2 diabetes mellitus. The various studies indicated 
switching to CSII therapy led to improved glucose control generally, reduction in 
daily insulin doses compared with conventional Multiple Dose Injection therapy 
(MDI) and improved patient satisfaction [5]. These studies were conducted in vari-
ous entities- Clinical Research Centers, Hospital outpatient clinics and small private 
outpatient offices.
Random Clinical Trials evaluating the efficacy of CSII therapy versus conven-
tional MDI have been conducted and published since 1991 [6–13]. Many of these 
earlier studies were shorter ranging from 16 to 32 weeks and showed minimal 
benefit of one modality over the other.
The OpT2mise trial included a large heterogeneous population noted significant 
benefit compared with MDI with lower HbA1C levels, decrease in insulin require-
ment and no significant change in weight and no change in hypoglycemic events. 
This was a large scale multi center international trial which compared the efficacy 
of CSII therapy to intensive MDI therapy in patients who were not able to reach 
HbA1C goals despite intensified MDI regimens. This was a randomized paral-
lel group study encompassing a run-in phase, 6-month randomized phase and a 
6-month continuation phase. To continue in the trial a minimum of 3 measurements 
of glucose per day was required [14].
The study noted that CSII therapy significantly improved blood glucoses in 
patients when compared with MDI regimens (~ mean difference was 0.7%). There 
was a 20% decrease in the total insulin dose per day with little or no change in 
hypoglycemic events or weight gain. Additionally, these results also indicate that 
selection of the proper individual for CSII treatment is paramount. The study also 
noted that ~ 38% of patients in the CSII treatment arm had mild cognitive impair-
ment. Patients with such impairments can successful implement CSII therapy with 
proper training and education.
This landmark study of CSII in Type 2 DM individuals does has some notable 
limitations. Patients with insulin resistance utilizing greater than 220 units per 
day were excluded. This is a large population which is increasing, and further 
large studies need to be considered. The study did not include individuals utilizing 
concentrated forms of insulin (U-200 and U-500).
Additionally, the study does not take in account the availability of continuous 
glucose monitoring and depended on serum blood glucose (SBG) monitoring. With 
the advent of flash glucose monitoring and advances in continuous glucose moni-
toring (CGM) discussed in another part of this chapter, additional studies compar-
ing CSII and MDI in these patients may be warranted.
At present, the CSII systems available for patients with Type 2 DM include 
pumps with sensor combinations that have the ability to suspend delivery if the 
sensor notes low glucose [15].
These systems are presently the only ones approved for patients with Type 2 DM.
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Future advances in CSII use for Type 2 DM could include the use of the hybrid 
closed loop system which now available for Type 1 DM individuals. The Medtronic 
hybrid closed loop system is the only one currently available. This system auto-
matically adjusts the basal delivery every 5 minutes based on sensor readings. The 
system attempts to maintain glucose levels to an assigned target [16]. This form of 
CSII therapy functions with two different modes: Auto mode which uses an algo-
rithm to respond to glucose levels. Manual mode is similar to previous pump-sensor 
combinations and requires preset basal rates by the individual in conjunction with 
his/her physician. Both systems still require manual meal bolus (MB) administra-
tion and manual correction for consistently elevated glucoses. Other companies are 
presently testing their versions of closed loop hybrid systems which may be avail-
able in the near future [17].
Patient with extreme insulin resistance have been at a disadvantage utilizing CSII 
therapy due to the restricted capacity of the pumps (either 180 units, 200 units, 
300 units). One company in Europe has developed small insulin pumps with 500 
unit and 800-unit capacity though this system is presently not available in the United 
States [18]. Physicians have resorted to utilizing U-500 in the pumps to decrease 
the frequency of site and pump changes. Several studies have noted the efficacy 
and improvement in quality of life with the use of U-500 in CSII therapy [19, 20]. 
Additional attempts to improve glucose control, quality of life, decreasing insulin 
requirements for Type 2 patients has led to use of so called “double pump” systems, 
utilizing insulin in 1 pump and pramlintide in an additional pump. Results in a 
small non-double-blind placebo-controlled observational study indicated a 10–20% 
decrease in insulin requirements, improvement in glucose control, weight loss and 
significant improvement in quality of life [21]. Limitations included the ability to 
obtain supplies for two separate pumps and utilization of pramlintide as this medica-
tion in vials was discontinued by the manufacturer at the direction of the FDA.
CSII therapy has been considered an improvement over traditional MDI therapy 
due to multiple factors: (1) There is predictable absorption of insulin. MDI which 
traditional requires injection of larger doses of insulin will form a depot and 
generally less efficacious in absorption and metabolic activity compared with CSII 
which involves smaller volumes [13]. Both the basal rate and meal bolus with CSII 
can be utilized with more precise insulin increments (tenths or hundredths of 
units). (2) Patients using CSII therapy appear to have increased satisfaction with 
this form of insulin therapy compared with traditional MDI injections. Based on 
personal observation and previous studies, patients find CSII more convenient 
for their lifestyle, easier to utilize after being trained and more likely to adhere to 
the treatment regimen. There is less likelihood of omitting (forgetting) their dose 
of insulin as compare with MDI. Peyrot et al. noted that patients record regular 
omission of insulin injections [22]. Personal observation of patients within my 
practice regularly indicates individuals utilizing MDI regularly admit missing meal 
time insulin injections. Those using CSII therapy note that since the insulin pump is 
attached and readily available, along with various alarm reminders missing doses is 
minimal. (3) The ability to download information from insulin pumps to websites 
(each pump has its own download capability which can cause increase work for the 
physician) can facilitate more efficient data collection and an ability to change the 
treatment regimen between patient visits.
Given the advantages of CSII therapy over MDI therapy, it would appear that 
CSII therapy should be considered for individuals with Type 2 DM as it is now 
considered for patients with Type 1 DM. However, cost effectiveness in several 
health systems has not been completely demonstrated. Current policies in many 
health systems are varied and the ability for patients to obtain access to CSII therapy 
may be limited.
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3. Continuous glucose monitoring (CGM)
Continuous glucose monitoring or CGM was first available for research projects 
in the 1970s.
Miles Laboratories in the late 1970s developed the Biostator which was large, 
bulky and required IV access. It had little use in everyday clinical practice, due to its 
size, need for constant supervision, IV access and waste of blood in order to mea-
sure glucose levels [23, 24].
In 2002, the GlucoWatch Biographer was introduced. It was shaped like a watch, 
similar to the Apple Watches of today. It adhered to the skin and used interstitial 
fluid to measure glucose levels every 10 minutes for 13 hours. [25]. See Figure 1.
Due to its process reverse iontophoresis, the GlucoWatch had significant draw-
backs. It was painful for many individuals, had accuracy issues and was difficult 
particularly in warmer climates with individuals sweating. The Autosensor, which 
was replaced every 13 hours had caused skin changes and irritation in many 
patients. Eventually the GlucoWatch was discontinued in late 2007. It did, however, 
pave the way for the CGM systems of today.
The current CGM systems use an enzymatic modality that reacts with interstitial 
fluid glucose and transfers it to an electrode. The electrical current that is generated 
is then relayed to a reader via Bluetooth wireless or an app on a smart phone which 
displays the results to the individual. The data can also be downloaded to a com-
puter. Additionally, the information can be stored to the cloud and relayed to the 
physician or caregiver via a secure website [26].
It must be noted that interstitial glucose measurements can lag 5–15 minutes 
behind blood glucose measurements particularly if there is rapid variability [27, 28]. 
Previously, CGM systems required calibrations twice per day which introduced a 
perceived limitation particularly for individuals who wished to limit “finger sticks” 
as an incentive to move to CGM systems.
The newer versions of CGM to include the DEXCOM G6, Guardian 3 and a flash 
form of CGM, the FreeStyle Libre (10-day and 14-day systems) have decreased the 
necessity of frequent calibrations.
In recent years, there have multiple studies with CGM involving individuals 
with Type 2 diabetes mellitus. The focus has been efficacy, the effect of CGM 
Figure 1. 
GlucoWatch Biographer 2.
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with regards to hypoglycemia and glucose variability [29]. A study conducted by 
Vigersky et al. with patients utilizing diet, lifestyle vs. other combinations of oral 
agent therapy with or without basal insulin noted a reduction of mean unadjusted 
HbA1C of 1.0% vs. 0.5% in the SMBG group at week 12 and 0.8% vs. 0.2% at week 
52. This occurred without intensification of medication or an increase in hypogly-
cemic episodes [29]. An additional study by Fonda et al. noted even an intermittent 
use of CGM may be appropriate for motivating individuals or helping to avoid 
“burnout” [30, 31].
The DiaMonD study (Daily Injections and Continuous Glucose Monitoring in 
Diabetes) study was a 6-month randomized control trial that compared the effec-
tiveness of CGM to SMBG in individuals using MDI (multiple daily injections). 
This included both Type 1 and Type 2 DM patients. The results of the 6-month 
trial for Type 2 patients was published in 2017 and noted the following: Type 2 DM 
individuals after 24 weeks using CGM had an average 0.8% reduction in HbA1C 
levels compared with baseline. Those with higher A1C levels noted the greatest 
reduction with a group starting with A1C levels greater than 9.0% noting an average 
1.4% reduction from baseline. Those using CGM had an increase in time spent in 
the target range compared with the control group (those only using SMBG). The 
A1C reductions occurred with minimal changes in insulin doses, little or no change 
in regimen or addition of non-insulin medications [32].
CGM has also been useful in recognizing previously undetectable episodes of 
hypoglycemia. Studies conducted by Zick et al.; Pazos-Couselo et al.; Klimontov 
and Myakina all noted a significant higher percentage of hyperglycemic episodes 
observed with the use of CGM compared with SMBG use.
The use of CGM particularly in older individuals utilizing insulin therapy has 
noted significantly higher incidences of nocturnal hypoglycemia compared with 
those utilizing only CGM. This indicates that CGM can be useful in high-risk Type 
2 DM populations such as the elderly, those with special needs and individuals that 
have difficulty utilizing HGM such as severe arthritic conditions, vascular issues, 
etc. [33–36].
CGM is also a tool to assess glucose variability. This has become important 
in outcome measurements recently in addition to the standard A1C levels. The 
INITIATION study which tested an insulin initiation algorithm in Type 2 DM 
patients used CGM in 78 patients who were followed for 24 weeks. The results noted 
that insulin initiation reduced hyperglycemia but not glucose variability [37, 38]. 
The FLAT-SUGAR study which randomized 102 patients who were on metformin 
and basal/bolus insulin to either maintenance with basal/bolus therapy for chang-
ing the basal insulin to GLP-1 therapy. The drug used with this study of 26 weeks 
was exenatide BID. Using CGM it was noted that the GLP-1 group had lower 
variability of glucose as measured by the coefficient of variation. Of note with 
this study, A1C levels or episodes of hypoglycemia did note change significantly 
between the treatment groups [39–41].
These studies and others both past and presently being conducted have shown 
the CGM use in patients with Type 2 DM can improve A1C levels, detect risk of 
hypoglycemia which is not clinically apparent, particularly nocturnally and may be 
able to assess and address glucose variability.
There are two forms of CGM presently available for use in clinical practice: 
(1) Professional CGM and (2) Personal CMG. Professional CGM is placed in the 
physician office and does not require the patient to obtain or purchase a system. 
It is a blinded system in many instances, that is, the patient has no access to the 
results immediately and must wait for the CGM to be downloaded in the physi-
cian’s office, analyzed and then informed of the results. These systems can be worn 
for 3, 7 or 14 days, though generally the 7- or 14-day systems are more popular 
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today. The systems available today in the United States for professional use are: the 
DEXCOM Professional system, the FreeStyle Libre Pro system, Medtronic iPro 2 
system. Most of these systems do require additional calibration. Once the study 
is completed, the data is downloaded to either the cloud or a specific program on 
the computer and then can be reviewed by the physician or allied health provider 
in conjunction with the physician and then shared with the patient. The blinded 
system can be helpful in regards that the patient is not responding during the time 
of the study but continuing their usual habits to include diet, activity and medica-
tions. Reimbursement for use of Professional CGM has improved over the past 
several years particularly in the United States. Requirements as the reporting of 
CGM results can vary among the different health plans which can lead to limita-
tions in its use.
Personal CGM consists of an individual obtaining a system which is unblinded 
and provides blood glucoses every 5+ minutes for DEXCOM and Guardian 3 
systems. These systems are placed subcutaneously and have alarms with notify the 
patient when certain patterns or thresholds are detected. There are multiple thresh-
old alarms, rate of change alarms, predictive alarms. Predictive alarms are useful 
in that it permits the individual to take preventative action rather than corrective 
action. However, the downside of these alarms is that there can be false positives 
and false negatives. This can lead to so-called “alarm fatigue” [42]. Individuals 
will in many instances either ignore or silence the systems due to the multitude 
of alarms. In some cases, they will abandon CGM altogether. The DEXCOM G5–6 
system is the only CGM device at present that is approved by the FDA for a non-
adjunctive indication. It can be considered a therapeutic CGM, allowing individuals 
and physicians to modify therapy based solely on the readings and trends.
The FreeStyle Libre system utilizes a flash monitoring system. It is placed like 
the other CGM systems subcutaneously but provides glucose results when the CGM 
is scanned. Thus, the results are intermittent depending on the frequency of scan-
ning by the patient [43]. The newest of the FreeStyle Libre systems, the 14-day unit 
improves over the older 10-day system with a 1-hour warm up period compared with 
12 hours. Several randomized controlled trails note that the use of flash CGM with the 
Libre system reduced hypoglycemia, increased the time in target range and reduced 
glucose variability [44, 45] Studies and personal observation have also shown higher 
device utilization. This may be due to the simplicity of application and ease of use. 
The use of this system in increasing and may prove to be an asset particularly in indi-
viduals who may not need the sophistication of the more complex CGM system but 
want the benefit of CGM and not have to consistently perform SMBG or finger sticks.
Additional studies in Europe have shown the cost effectiveness of CGM in the 
management of patients with Type 2 DM receiving intensive MDI regimens and 
also improvement in the detection and avoidance of hypoglycemia in individuals 
with Type 2 DM [46, 47].
Another technological advance in CGM has been the development and approval 
of the implantable CGM system by Senseonics called the Eversense System. The 
system consists of an implantable cylindrical sensor 3.5 mm × 18.3 mm in size. 
This is implanted by the physician every 90 days in the upper arm area under the 
skin. When the system in activated, it measures interstitial glucose levels every 
5 minutes. The data is transferred to a battery powered transmitter that is worn 
externally over the sensor. The external transmitter also provides alerts similar to 
other CGM systems for impending hypo or hyperglycemia. The transmitter needs 
to be recharged for ~15 minutes every other day. The sensor is explanted, and a new 
sensor implanted every 90 days. A 180-day sensor is being developed for the future.
Several studies have shown the accuracy and acceptability of an implantable 
glucose sensor. The PRECISE and PRECISE II studies noted that the Eversense 
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system was safe and provided accurate glucose results during the 90-day sensor 
life [48, 49]. An additional study in the UK and Germany comprising a subgroup 
of individuals in the PRECISE trial who were administered quantitative psycho-
social assessments that included the Diabetes Distress Scale (DDS), CGM Impact 
Scale and a bespoke device satisfaction questionnaire. The results of the sub study 
indicated that an implantable CGM was acceptable to most of the participants 
and the majority of users both first time to CGM or previous CGM users would 
continue to use an implantable CGM to manage their glucoses and DM more 
effectively [50].
As the accuracy of CGM improves, particularly in the hypoglycemia range, 
the acceptance should also increase. However, at this time, CGM still does not, in 
the eyes of the regulatory agencies substitute fully for conventional SBGM. With 
continued development and use, it appears that eventually CGM, with or without 
CSII therapy will become the “standard of care” for both Type 1 and Type 2 diabetes 
mellitus.
4. Smart pen systems
Most individuals with DM, particularly Type 2 DM, who utilize insulin therapy 
are using insulin pen systems to deliver their daily insulin dose. Previous adminis-
tration of insulin via syringe and vial has been difficult to administer and master. 
Additionally, accuracy of dose has been questioned. Insulin pens are one of the most 
widely used devices worldwide in DM treatment and care [51].
A recent review of the literature and meta-analysis noted that insulin pen 
devices noted improvement in patient adherence and persistence with their treat-
ment regimen. Hypoglycemia was noted to be reduced, with a possible improve-
ment in dose accuracy in pen devices. However, these studies were limited, and the 
authors of the meta-analysis recommended additional larger scale studies [52].
Additionally, there is the issue of documentation of insulin doses. Many patients 
do not record the time and dose of insulin consistently. Many will state that they 
took their insulin with meals, nighttime, for correction of their glucose, etc. but will 
not be able to provide accurate documentation. Therefore, this can be a significant 
barrier to glycemic control. Guidelines developed by various organizations make 
no mention of the need to record insulin dose administered and timing of injection 
whether the patient uses pen or syringe/vial.
In December 2017, the FDA approved the first smart pen system in the US. This 
insulin pen system records the dose of insulin and time of injection and transmits 
the data via Bluetooth to a mobile application that is downloaded on the patient’s 
smart phone. The mobile app has the capability of dose calculation and less than 
whole number units which conventional insulin pens are not able to deliver.
It can also inform the individual how much insulin is on board (IOB) similar to 
CSII devices. This data is stored on the individuals’ smart phone and can be brought 
easily to the clinical visit for analysis by the physician/health care provider.
There may an additional entry in this area. Bigfoot Biomedical is developing an 
insulin smart pen that will connect to the FreeStyle Libre system. It will be con-
trolled with a mobile app and hopefully adjust long and short acting insulin doses 
without manual input [53].
The benefits of a smart pen system in the treatment of individuals with DM can 
be summarized as follows:
1. Improvement in poor adherence to the treatment regimen and omission of 
insulin doses.
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Having the data readily available and reminders on their phone can provide an 
extra incentive to be more compliant with their regimen.
2. Improvement with the risk of insulin dose errors. Access to dosing and timing 
of insulin can facilitate more accurate doses and limit the risk of accidental 
overdose or under dosing.
This being a relatively new technology, these devices will need to demonstrate 
improvement in clinical and QOL (Quality of Life) outcomes, cost effectiveness, 
ease of training and use. However, many of the technologies discussed above have 
underwent the same scrutiny. The issue of cybersecurity as with any connected DM 
devices will need to be resolved to maintain patient confidentiality and integrity 
of the data. Smart pens may be an alternative to individuals who do not want CSII 
therapy for a multitude of reasons but would like to intensify their regimen and 
have access to appropriate dosing and timing of insulin to improve their glucose 
control.
5. Mobile and computer applications (apps)
Data Management software for diabetes has been available since the late 1980s 
to early 1990s. However, acceptance and adoption by both patients and physicians 
has been slow. The issues have been the ability to download or upload data with each 
device having its own set of software and cable connections. In many cases, physi-
cian offices had upwards of 6–10 different connections to obtain data from SMBG 
meters and other devices.
Over the past two decades, a number of innovations were developed that 
“streamlined” the ability to obtain data from patient devices. There has been an 
improvement in device connectivity with most devices now able to utilize Bluetooth 
technology thus eliminating the need for multiple cables or hubs. Additionally, 
smartphone technology has decreased the cost and complexity of data sharing. The 
use of automated uploads from devices to the “cloud” has allowed both patient and 
physician to have almost real-time access to data [53].
Proprietary cloud data platforms from multiple device manufacturers have been 
able to provide secure data and have developed common formats, easing the burden 
on physicians and their offices to maintain multiple programs. Also, many of the 
device companies, including those manufacturing SMBG devices have developed 
complex reporting capabilities that have been designated as Ambulatory Glucose 
Reports or Profiles.
The multitude of apps for the patient with DM has led to concerns of quality and 
safety. Apps available at both the Google Play store and Apple App Store may little or 
no oversight. A recent study in 2016 found that the majority of apps from the Google 
Play store did not meet the minimum requirements or did not work appropriately 
[54, 56] Additional studies are needed to fully investigate the efficacy and utility of 
mobile applications with regard to the treatment of individuals with Type 2 DM.
Another approach is to combine the mobile application, the cloud with a remote 
coaching system. Studies are now ongoing to assess the effect of individuals using 
a smart phone-based glucose monitoring system which automatically moves data 
to a secure cloud-based site [55]. A designated “diabetes coach” which is a health 
care provider (RN, NP or physician) then reviews the data several times per week 
and remotely connects with the patient to provide recommendations or discussion. 
Results are pending in these studies and hopefully preliminary results will be avail-
able in 2019. (Personal Observation).
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The use of Artificial Intelligence (AI) in the treatment of patients with Diabetes is 
emerging and advancing at significant pace. Multiple programs are being developed 
to improve adherence and personalize the individual’s regimen. Studies are ongoing 
to determine whether pattern recognition and the ability of machine learning can 
provide the patient with diabetes mellitus a unique, individualize model which is 
automated and can assist with predictions and decisions. At this time, AI cannot and 
does not substitute for patient – physician interaction and communication.
6. Conclusion
This chapter attempted to briefly outline the technological advances in the 
treatment of Type 2 diabetes mellitus. It is noted the technology has improved the 
quality of life, blood glucose control and possibly decreased the risk of complica-
tions. However, it must be pointed out to the reader that technology, no matter how 
advanced, does not substitute for personal interaction with patients. The ability 
to know your patient, his/her lifestyle, stressors, etc. plays an important role in 
designing the proper treatment regimen. Continued advances in technology will in 
the future make the physician/healthcare provider and the patient’s ability to con-
trol his/her blood glucoses less complicated but ultimately the decisions to maintain 
diet, exercise, monitoring of glucoses remains with the individual.
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